Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Jun;67(6):879-883.
doi: 10.4103/ijo.IJO_2115_18.

The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity

Muberra Akdogan  1 , Sadik Gorkem Cevik  2 , Ozlem Sahin  3
Affiliations
Observational Study

The safety and effectiveness of 0.16 mg bevacizumab plus or minus additional laser photocoagulation in the treatment of retinopathy of prematurity

Muberra Akdogan et al. Indian J Ophthalmol. 2019 Jun.

Abstract

Purpose: Retinopathy of prematurity (ROP) is the leading cause of preventable blindness in premature infants. Antivascular endothelial growth factor (anti-VEGF) therapy has been used increasingly in treatment as a pharmacological alternative to laser therapy. In this study, we evaluate the results of low-dose anti-VEGF treatments.

Methods: Design: Retrospective--observational study. Infants who had been evaluated for ROP disease between February 2016 and February 2017 were assessed. We retrospectively reviewed the ROP stages, treatment results, and complications. Laser photocoagulation (LPC) and intravitreal bevacizumab (0.16 mg IVB) were used for treatment and fundus fluorescein angiography (FFA) was also performed in some of the cases.

Results: IVB was applied to 43 infants. A macular hole was seen in one infant's eye after IVB. LPC was applied to avascular areas in 21 infants. In three patients, persistence of the disease was observed after administration of a low dose of IVB. Additional LFK was performed in these patients. None of the infants who received LPC had any complications.

Conclusion: IVB is increasingly becoming the first-line treatment for ROP. For severe ROP, 0.16 mg IVB is effective. Using LPC to treat avascular areas after 70 weeks' gestational age (GA) may decrease the risk of late recurrence and appears to be a safe treatment to use.

Keywords: Complication; laser photocoagulation; macular hole; retinopathy of prematurity; ultra-low-dose bevacizumab.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Preoperative macular hole on OCT image
Figure 2
Figure 2
Vascular arrest seen on FFA
Figure 3
Figure 3
Abnormal arteriovenous communication and vascular arrest seen on FFA
Figure 4
Figure 4
Peripheral avascular area and vascular leakage on FFA image
Figure 5
Figure 5
Abnormal vascular connection on FFA image
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert G. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013;74:35–49. - PMC - PubMed
    1. Zin A, Gole GA. Retinopathy of prematurity-incidence today. Clin Perinatol. 2013;40:185–200. - PubMed
    1. Ergenekon E, Turan O, Ozdek S. Retinopathy of prematurity in Turkey. Cocuk Sagligi ve Hastalýklari Dergisi. 2010;53:4–9.
    1. Fierson WM. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013;133:189–95. - PubMed
    1. Gilbert G. Retinopathy of prematurity a global perspective of epidemics, population of babies at risk and implications for control. Early Hum Dev. 2008;84:77–82. - PubMed

Publication types

MeSH terms

Substances